Participants will remain at the study site for observation for a minimum of 30 minutes so clinicians can monitor for any adverse reactions. The study team will review patient data daily and weekly to monitor safety. The study is part of the U.S. government response to the ongoing outbreak of Zika virus in the Americas. This is the first administration of this vaccine in a human. In the United States and its territories, more than 6,400 Zika cases have been reported. “A safe and effective vaccine to prevent Zika virus infection and the devastating birth defects it causes is a public health imperative,” said NIAID Director Anthony S. Fauci.
To become publicly available a vaccine must be tested in many phases but regarding this one there is possibly it will not be a second phase unless Congress breaks an impasse over federal funding to combat the mosquito-borne disease.
